Altered subcellular localization of c-myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation

American Journal of Surgical Pathology

Volumn 34, Issue 6, 2010, Pages 882-891

  Ruzinova, Marianna B ^a   Caron, Tyler ^a   Rodig, Scott J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Burkitt lymphoma; C myc; Diffuse large B cell lymphoma; Immunohistochemistry

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; BURKITT LYMPHOMA; CELL NUCLEUS; CYTOPLASM; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; METABOLISM; METHODOLOGY; OBSERVER VARIATION; ONCOGENE MYC;

ANTIBODIES, MONOCLONAL; BURKITT LYMPHOMA; CELL NUCLEUS; CYTOPLASM; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; OBSERVER VARIATION; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC;

EID: 77953030981     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181db83af     Document Type: Article

References (25)

1. Barth TF, Muller S, Pawlita M, et al. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. J Pathol. 2004;203:940-945.
2. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218-223.
3. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824-7827.
4. Dalla-Favera R, Westin E, Gelmann EP, et al. The human onc gene c-myc: structure, expression, and amplification in the human promyelocytic leukemia cell line HL-60. Haematol Blood Transfus. 1983;28:247-254.
5. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
6. Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16:1928-1935.
7. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
8. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
9. Jack AS, Kerr IB, Evan G, et al. The distribution of the c-myc oncogene product in malignant lymphomas and various normal tissues as demonstrated by immunocytochemistry. Br J Cancer. 1986;53:713-719.
10. Jaffe ES HN, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
11. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t (14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25-33.
12. Loke SL, Neckers LM, Schwab G, et al. c-myc protein in normal tissue. Effects of fixation on its apparent subcellular distribution. Am J Pathol. 1988;131:29-37.
13. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
14. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976-990.
15. Mitani S, Sugawara I, Shiku H, et al. Expression of c-myc oncogene product and ras family oncogene products in various human malignant lymphomas defined by immunohistochemical techniques. Cancer. 1988;62:2085-2093.
16. Rodig SJ, Vergilio JA, Shahsafaei A, et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32:113-122.
17. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-3537.
18. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3:1133-1137.
19. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327-340.
20. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664-674.
21. Steven H, Swerdlow EC, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
22. Tao Q, Robertson KD, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 1998;91:1373-1381.
23. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79:7837-7841.
24. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308-318.
25. Yunis JJ, Mayer MG, Arnesen MA, et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989;320:1047-1054.